Commercial Pharma’s Business Case for Digital Health Solutions

Every digital health solution must be anchored in a compelling, well-structured business case — one that demonstrates measurable ROI, earns stakeholder confidence, and secures sustainable investment. For pharmaceutical companies, that means showing clear alignment with core objectives: supporting brand revenue through increased medicine sales, while advancing medical innovation and improving patient outcomes. In an era of heightened competition and evolving market pressures, building this case is no longer optional — it’s a strategic imperative. 

This whitepaper draws on the expertise of leaders from Novo Nordisk, Merck, Roche, and S3 Connected Health to outline a proven approach for evaluating, developing, and embedding digital health solutions into brand strategies. It reveals how a strong evidence framework can help organizations navigate each stage of the commercial lifecycle — from early market preparation and launch to differentiation and loss of exclusivity (LOE). 

Designed for decision-makers in pharma, this guide focuses on high-value therapies targeting chronic, complex, and rare diseases, where digital health plays a pivotal role in patient engagement and long-term treatment success. It provides actionable steps to avoid investment missteps, strengthen cross-functional alignment, and unlock real-world value. 

In this whitepaper, you’ll learn how to: 

• Overcome revenue barriers by aligning digital health to brand and enterprise priorities
• Identify opportunities to drive impact at every stage of the drug lifecycle
• Build robust, ROI-driven business cases that secure internal approval
• Integrate digital health early to accelerate adoption and differentiation
• Tailor strategies for high-value therapies in complex patient populations

File Size: 2.5 MB